The effects of gliclazide on platelet function in patients with diabetes mellitus.
Eighteen diabetic patients with abnormal platelet function were treated for 1 month with gliclazide (80 to 160 mg/day). Platelet aggregation, circulating beta-thromboglobulin levels and platelet malondialdehyde concentrations were significantly reduced after 30 (but not 15) days of treatment. Although fasting and post-prandial glycaemia significantly improved in these patients, similar changes in platelet function were noted in 5 other patients in whom glycaemia did not change. Gliclazide therapy, therefore, brought about an improvement in platelet function and a reduction activation in the thromboxane metabolic pathway, possibly by a direct on the platelets.
D000328:Adult; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005907:Gliclazide / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D013453:Sulfonylurea Compounds / Q000494:pharmacology*; D013931:Thromboxanes / Q000378:metabolism
D013453:Sulfonylurea Compounds; D013931:Thromboxanes; D005907:Gliclazide